Observational studyScientific reports2020
Claudin-1 decrease impacts epidermal barrier function in atopic dermatitis lesions dose-dependently.
Observational study in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Nano intervention in topical delivery of corticosteroid for psoriasis and atopic dermatitis-a systematic review.Journal of materials science. Materials in medicine · 2021Pooled it
- Commensal Cutibacterium acnes-derived indolelactic acid safeguards skin barrier function through the aryl hydrocarbon receptor.Cell reports. Medicine · 2026Trial
- Age-adjusted machine learning identifies facial skin microbes associated with skin quality among Korean women.mSystems · 2026Article
- Self-Assembled Nanoparticles of Licorice Extract Enhance Skin Penetration and Regulate Barrier Proteins via a Dual-Channel Pathway.Pharmaceutics · 2026Article
- Valorization of Chum Salmon (Marine drugs · 2026Article
- Epithelial Barrier Dysfunction in Atopic Dermatitis, Allergic Contact Dermatitis, and Chronic Spontaneous Urticaria and its Therapeutic Implications.Current allergy and asthma reports · 2026Review
- Article
- Polymorphic light eruption shows aberrant expression of epidermal tight junction proteins in unexposed and UVR-exposed skin: an experimental study.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- Linoleic acid concentration at the air-liquid interface is key for optimal incorporation into skin model lipidome.Frontiers in physiology · 2026Article
- Evaluation of the safety and functional effects of recombinant humanized type III collagen in food toxicology.Frontiers in medicine · 2026Article
- STAT3 ablation in keratinocytes ameliorates allergic contact dermatitis in DNCB-induced mice model.Iranian journal of basic medical sciences · 2026Article
- Review
- Schistosoma haematobium infection is associated with oncogenic gene expression in Cervical Mucosa, with enhanced effects following treatment: A pilot study.PLoS neglected tropical diseases · 2025Article
- The role of skin barrier and immune abnormalities in the pathogenesis of Rosacea.Clinical and experimental medicine · 2025Review
- Vitamin D and Atopic Dermatitis-A Mere Correlation or a Real Supportive Treatment Option?Nutrients · 2025Review
- Perfluorononanoic Acid (PFNA) Exacerbates Atopic Dermatitis by Inducing Inflammation in Mice.Toxics · 2025Article
- The PAR2 Antagonist Larazotide Can Mitigate Acute Histamine-Stimulated Epithelial Barrier Disruption in Keratinocytes: A Potential Adjunct Treatment for Atopic Dermatitis.JID innovations : skin science from molecules to population health · 2025Article
- IFN-α and vitamin B6-induced galectin-9 promotes the immunomodulatory function of human clonal mesenchymal stem cells.Stem cell research & therapy · 2025Article
- Hydrodynamically generated multilayer skin spheroids enable in vitro screening of biologically active ingredients and toxicity tests.Science advances · 2025Article
- Claudin 1 dysregulation disrupts coronary microvascular integrity and impairs cardiac function.Atherosclerosis · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transmembrane protein claudin-1 is a major component of epidermal tight junctions (TJs), which create a dynamic paracellular barrier in the epidermis. Claudin-1 downregulation has been linked to atopic dermatitis (AD) pathogenesis but variable levels of claudin-1 have also been observed in healthy skin. To elucidate the impact of different levels of claudin-1 in healthy and diseased skin we determined claudin-1 levels in AD patients and controls and correlated them to TJ and skin barrier function. We observed a strikingly broad range of claudin-1 levels with stable TJ and overall skin barrier function in healthy and non-lesional skin. However, a significant decrease in TJ barrier function was detected in lesional AD skin where claudin-1 levels were further reduced. Investigations on reconstructed human epidermis expressing different levels of claudin-1 revealed that claudin-1 levels correlated with inside-out and outside-in barrier function, with a higher coherence for smaller molecular tracers. Claudin-1 decrease induced keratinocyte-autonomous IL-1β expression and fostered inflammatory epidermal responses to non-pathogenic Staphylococci. In conclusion, claudin-1 decrease beyond a threshold level results in TJ and epidermal barrier function impairment and induces inflammation in human epidermis. Increasing claudin-1 levels might improve barrier function and decrease inflammation and therefore be a target for AD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.